Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure

Advances in Protein Chemistry and Structural Biology

Volumn 85, Issue , 2011, Pages 1-26

  Lodola, Alessio ^a   Rivara, Silvia ^a   Mor, Marco ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052788690     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386485-7.00001-6     Document Type: Chapter

References (60)

1. K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, and T. Stevenson Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 46 2007 13019 13030 (Pubitemid 350086220)
2. J.P. Alexander, and B.F. Cravatt Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes Chem. Biol. 12 2005 1179 1187 (Pubitemid 41628253)
3. A.D. Andricopulo, L.B. Salum, and D.J. Abraham Structure-based drug design strategies in medicinal chemistry Curr. Top. Med. Chem. 9 2009 771 790
4. J. Aqvist, and J. Marelius The linear interaction energy method for predicting ligand binding free energies Comb. Chem. High. Throughput Screen. 4 2001 613 626 (Pubitemid 34003156)
5. F.R. Bambico, A. Duranti, A. Tontini, G. Tarzia, and G. Gobbi Endocannabinoids in the treatment of mood disorders: evidence from animal models Curr. Pharm. Des. 15 2009 1623 1646
6. E. Basso, A. Duranti, M. Mor, D. Piomelli, A. Tontini, and G. Tarzia Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters J. Mass Spectrom. 39 2004 1450 1455 (Pubitemid 39664930)
7. M.H. Bracey, M.A. Hanson, K.R. Masuda, R.C. Stevens, and B.F. Cravatt Structural adaptation in a membrane enzyme that terminates endocannabinoid signaling Science 298 2002 1793 1796 (Pubitemid 35404124)
8. D. Branduardi, F.L. Gervasio, and M. Parrinello From A to B in free energy space J. Chem. Phys. 126 2007 054103
9. H.A. Carlson, and W.L. Jorgensen An extended linear response method for determining free energies of hydration J. Phys. Chem. 99 1995 10667 10673
10. C. Carmi, A. Cavazzoni, S. Vezzosi, F. Bordi, F. Vacondio, and C. Silva Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion J. Med. Chem. 53 2010 2038 2050
11. J.R. Clapper, F. Vacondio, A.R. King, A. Duranti, A. Tontini, and C. Silva A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo ChemMedChem 4 2009 1505 1513
12. J.R. Clapper, G. Moreno-Sanz, R. Russo, A. Guijarro, F. Vacondio, and A. Duranti Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism Nat. Neurosci. 13 2010 1265 1270
13. F. Colizzi, R. Perozzo, L. Scapozza, M. Recanatini, and A. Cavalli Single-molecule pulling simulations can discern active from inactive enzyme inhibitors J. Am. Chem. Soc. 132 2010 7361 7371
14. M. De Vivo Bridging quantum mechanics and structure-based drug design Front. Biosci. 16 2011 1619 1633
15. Y. Deng, and B. Roux Computations of standard binding free energies with molecular dynamics simulations J. Phys. Chem. B 113 2009 2234 2346
16. A.D. Favia Theoretical and computational approaches to ligand-based drug discovery Front. Biosci. 16 2011 1276 1290
17. M.J. Field, P.A. Bash, and M. Karplus A combined quantum-mechanical and molecular mechanical potential for molecular-dynamics simulations J. Comput. Chem. 11 1990 700 733
18. A. Fiser, M. Feig, C.L. Brooks 3rd, and A. Sali Evolution and physics in comparative protein structure modeling Acc. Chem. Res. 35 2002 413 421
19. S. Gattinoni, C. De Simone, S. Dallavalle, F. Fezza, R. Nannei, and D. Amadio Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system ChemMedChem 5 2010 357 360
20. A. Ghosh, C. Sendrovic Rapp, and R.A. Friesner Generalized Born model based on a surface integral formulation J. Phys. Chem. B 102 1998 10983 10990 (Pubitemid 128716615)
21. C. Hansch, and A. Leo Exploring QSAR. Fundamentals and Applications in Chemistry and Biology 1995 American Chemical Society Washington, DC
22. L.W. Hardy, D.J. Abraham, and M.K. Safo Structure based drug design D.J. Abraham, Burger's Medicinal Chemistry and Drug Discovery vol. 1 2003 John Wiley & Sons Hoboken 417 469
23. W.L. Jorgensen Efficient drug lead discovery and optimization Acc. Chem. Res. 42 2009 724 733
24. S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, and A. Tontini Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81 (Pubitemid 36098263)
25. D.B. Kitchen, H. Decornez, J.R. Furr, and J. Bajorath Docking and scoring in virtual screening for drug discovery: methods and applications Nat. Rev. Drug Discov. 3 2004 935 949 (Pubitemid 39529931)
26. G. Klebe Virtual ligand screening: strategies, perspectives and limitations Drug Discov. Today 11 2006 580 594
27. R.T. Kroemer Structure-based drug design: docking and scoring Curr. Protein Pept. Sci. 8 2007 312 328 (Pubitemid 47317039)
28. A.R. Leach, B.K. Shoichet, and C.E. Peishoff Prediction of protein-ligand interactions. Docking and scoring: successes and gaps J. Med. Chem. 49 2006 5851 5855 (Pubitemid 44484931)
29. A. Lodola, M. Mor, J.C. Hermann, G. Tarzia, D. Piomelli, and A.J. Mulholland QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation Chem. Commun. 2005 4399 4401 (Pubitemid 41375016)
30. A. Lodola, M. Mor, S. Rivara, C. Christov, G. Tarzia, and D. Piomelli Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling Chem. Commun. 2008 214 216 (Pubitemid 350294105)
31. A. Lodola, M. Mor, J. Sirirak, and A.J. Mulholland Insights into the mechanism and inhibition of fatty acid amide hydrolase from quantum mechanics/molecular mechanics (QM/MM) modeling Biochem. Soc. Trans. 37 2009 363 367
32. A. Lodola, L. Capoferri, S. Rivara, E. Chudyk, J. Sirirak, and E. Dyguda-Kazimierowicz Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling Chem. Commun. 47 2011 2517 2519
33. R. Lonsdale, K.E. Ranaghan, and A.J. Mulholland Computational enzymology Chem. Commun. 46 2010 2354 2372
34. A.D. MacKerell, D. Bashford, M. Bellott, R.L. Dunbrack, J.D. Evanseck, and M.J. Field All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. A 102 1998 3586 3616 (Pubitemid 128576688)
35. G.R. Marshall, and D.D. Beusen Molecular modelling in drug design D.J. Abraham, Burger's Medicinal Chemistry and Drug Discovery vol. 1 2003 John Wiley & Sons Hoboken 77 168
36. M.K. McKinney, and B.F. Cravatt Structure and function of fatty acid amide hydrolase Annu. Rev. Biochem. 74 2005 411 432 (Pubitemid 40995513)
37. J. Michel, and J.W. Essex Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations J. Comput. Aided. Mol. Des. 24 2010 639 658
38. M. Mileni, S. Kamtekar, D.C. Wood, T.E. Benson, B.F. Cravatt, and R.C. Stevens Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation J. Mol. Biol. 400 2010 743 754
39. A. Minkkilä, S. Saario, and T. Nevalainen Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors Curr. Top. Med. Chem. 10 2010 828 858
40. M. Mor, and A. Lodola Pharmacological tools in endocannabinoid neurobiology Curr. Top. Behav. Neurosci. 1 2009 87 110
41. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, and A. Duranti Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modelling studies J. Med. Chem. 47 2004 4998 5008 (Pubitemid 39314898)
42. M. Mor, S. Rivara, A. Lodola, S. Lorenzi, F. Bordi, and P.V. Plazzi Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors Chem. Biodivers. 2 2005 1438 1451 (Pubitemid 41762897)
43. M. Mor, A. Lodola, S. Rivara, F. Vacondio, A. Duranti, and A. Tontini Synthesis and structure-reactivity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates J. Med. Chem. 51 2008 3484 3498
44. G.G. Muccioli Endocannabinoid biosynthesis and inactivation, from simple to complex Drug Discov. Today 15 2010 474 483
45. A.J. Mulholland Modelling enzyme reaction mechanisms, specificity and catalysis Drug Discov. Today 10 2005 1393 1402 (Pubitemid 41501794)
46. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Invest. Drugs 11 2010 51 62
47. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884 (Pubitemid 37351427)
48. D. Piomelli The endocannabinoid system: a drug discovery perspective Curr. Opin. Invest. Drugs 6 2005 672 679 (Pubitemid 40904037)
49. D. Piomelli, G. Tarzia, A. Duranti, A. Tontini, M. Mor, and T.R. Compton Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597) CNS Drug Rev. 12 2006 21 38 (Pubitemid 44133578)
50. M. Seierstad, and J.G. Breitenbucher Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 51 2008 7327 7343
51. C.D. Selassie History of quantitative structure-activity relationship D.J. Abraham, Burger's Medicinal Chemistry and Drug Discovery vol. 1 2003 John Wiley & Sons Hoboken 1 48
52. H.M. Senn, and W. Thiel QM/MM methods for biomolecular systems Angew. Chem. Int. Ed. 48 2009 1198 1229
53. S.Y. Sit, C. Conway, R. Bertekap, K. Xie, C. Bourin, and K. Burris Novel inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 17 2007 3287 3291 (Pubitemid 46830893)
54. C. Solorzano, F. Antonietti, A. Duranti, A. Tontini, S. Rivara, and A. Lodola Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl) amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors J. Med. Chem. 53 2010 5770 5781
55. G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, M. Mor, and S. Rivara Design, synthesis, and structure-activity relationship of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 46 2003 2352 2360 (Pubitemid 36637920)
56. G. Tarzia, A. Duranti, G. Gatti, G. Piersanti, A. Tontini, and S. Rivara Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring ChemMedChem 1 2006 130 139 (Pubitemid 44104985)
57. A. Tropsha Recent trends in quantitative structure-activity relationship D.J. Abraham, Burger's Medicinal Chemistry and Drug Discovery vol. 1 2003 John Wiley & Sons Hoboken 49 76
58. F. Vacondio, C. Silva, A. Lodola, A. Fioni, S. Rivara, and A. Duranti Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability ChemMedChem 4 2009 1495 1504
59. B.O. Villoutreix, R. Eudes, and M.A. Miteva Structure-based virtual ligand screening: recent success stories Comb. Chem. High Throughput Screen. 12 2009 1000 1016
60. C.J. Woods, M. Malaisree, S. Hannongbua, and A.J. Mulholland A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies J. Chem. Phys. 134 2011 054114